Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

'Histone Deacetylase 4 - Pipeline Review, H2 2017'; Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes.

The report 'Histone Deacetylase 4 - Pipeline Review, H2 2017' outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Key Topics Covered:

1. Introduction
2. Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview
3. Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development
4. Products under Development by Stage of Development
5. Products under Development by Therapy Area
6. Products under Development by Indication
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

• 4SC AG
• HitGen LTD
• MEI Pharma Inc
• Mirati Therapeutics Inc
• Sigma-Tau SpA

For more information about this report visit https://www.researchandmarkets.com/research/964ck6/histone